$2.8M grant awarded for study on gum disease and Alzheimer's link
AUGUSTA, Ga. (WJBF) – A doctor at the Dental College of Georgia has been awarded a grant to continue research on the connection between gum disease and Alzheimer's disease.
The $2.8 million competitive grant was awarded to Dr. Ranya El Sayed by the National Institute of Aging.
Dr. El Sayed said there is a strong relationship between gum disease and Alzheimer's disease, which led to the question – how does this happen and is there a cause-and-effect relationship?
El Sayed said, 'During periodontal infection in the gums, the immune cells release small particles that are called exosomes. These exosomes are capable of traveling through the blood stream to cross the blood brain barrier and when they enter the blood brain barrier, their taken up by the immune cells of the brain which are called microglia cells and this causes neuroinflammation and inflammation of the brain.'
According to the Alzheimer's Association, nearly 7 million Americans are living with the disease, by 2050 that number is projected to reach almost 13 million.
Dr. Babak Baban, Professor and Associate Dean of Research for Dental College of Georgia, says it's an honor to have their research be noticed and appreciated by such a large organization.
'A topic like this which can secure the competitive funding really at the national level, that means a lot, that speaks for itself that our faculty and our researchers are basically discovering the innovative ways to improve our health quality and our life quality in general.' Dr. Baban said.
Over the course of her research, Dr. El Sayed says the most fascinating thing she learned was how interconnected the brain and mouth truly are.
She said Alzheimer's is such a devastating disease and hopes their findings will impact people in the future.
She said, 'We are still working on it, we have very promising data from human data, mice data, and that we are still working on it, there is a lot more to answer and I'm very optimistic we are going to find something by the end of the research period.'
She continued to say, 'If we treat the root cause from the beginning, if we are able to raise awareness in Alzheimer's patients or in the early stages, or elderly patients or the whole population in general to take care of their teeth and do the maintenance visits, the routine dental visits, we can eliminate the problem, maybe.'
Dr. El Sayed's team has been researching this correlation for the past 3 and a half years and this grant will allow them to continue their research for the next 5 years.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
5 hours ago
- Epoch Times
Why Drug Price Reform Alone Won't Heal America
President Donald Trump's revived effort to reduce prescription drug prices is a long-overdue step toward affordability. For millions of Americans, the cost of staying alive has become burdensome, and any policy that eases the burden is worth celebrating. However, as a physician, I've seen what happens when medications become too cheap, plentiful, and automatic. If we don't reform how drugs are used, we risk trading financial hardship for clinical harm. Vagaries of Lower Drug Costs In today's health care system, medication is the first answer—and often the last, especially for older adults. More than 40
New York Post
7 hours ago
- New York Post
Study reveals major health upside of going through menopause later
Most women can't wait to give Aunt Flo the boot. After all, she's moody, messy and shows up uninvited every month. But new research suggests that having more years between your first period and your last comes with some serious health perks later in life. And it has nothing to do with what's happening below the belt. 4 When women enter menopause, they stop menstruating and can no longer get pregnant naturally. Syda Productions – In the study, University of Auckland researchers analyzed brain scans from more than 1,000 postmenopausal women and spotted a striking pattern. Those who got their first period earlier, went through menopause later or simply had more years in between showed noticeably slower signs of brain aging. 'These findings support the idea that estradiol — the most potent and prevalent form of estrogen during a woman's reproductive years — may help protect the brain as it ages,' said Dr. Eileen Lueders, lead researcher of the study. In animal studies, estradiol has been found to support brain health by enhancing neuroplasticity, reducing inflammation and improving communication between brain cells. 4 Women are disproportionately affected by Alzheimer's disease. kangwan – Estradiol levels fluctuate throughout a woman's life. They rise sharply at puberty, stay high during most of the reproductive years, then drop steeply around menopause. Previous studies have linked that decline in estradiol levels to an increased risk of dementia and other age-related brain conditions. The findings suggest that health interventions, such as hormone treatment, in the years leading up to menopause and immediately after could help combat an increased risk of Alzheimer's for some women, researchers said. The stakes are high: Women bear the brunt of the memory-robbing disease, making up about two-thirds of the 7 million cases across the US today, according to the Alzheimer's Association. 4 A first period is typically a sign that a girl is nearing the end of puberty. Sarah Rypma – In the US, girls usually start menstruating around age 12, though the Mayo Clinic reports that periods can begin as early as 8 or as late as 16. The years when a woman menstruates and can get pregnant are called the reproductive phase. This stage ends with menopause, which is officially diagnosed after a woman has gone 12 months without a period. The average women in the US hits menopause around age 51, but it can happen anytime from the 30s to the mid-50s or later, according to the federal Office on Women's Health. The age you enter menopause is influenced by several factors, including genetics, lifestyle and certain medical conditions. For example, women who smoke may enter menopause earlier, while having multiple pregnancies can delay its onset. 4 The years leading up to menopause are often accompanied by uncomfortable symptoms like hot flashes. Monkey Business – 'As more women weigh the benefits of hormone therapy during menopause, findings like these spark important conversations and open the door to more inclusive, focused research in women's brain health,' said Alicja Nowacka, a PhD student at the University of Auckland who wasn't involved in the study. While the new research adds to the growing evidence that estradiol may help protect brain health, Lueders cautioned that the effects were small and estradiol levels were not directly measured. She also noted that other factors, such as genetics, lifestyle and overall health, can play a role in brain aging. Looking ahead, Lueders is urging future studies to include a more diverse pool of participants and directly measure their hormone levels to better understand how estradiol and other factors impact women's brain health.
Yahoo
10 hours ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
